BRPI0409046A - sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos - Google Patents

sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos

Info

Publication number
BRPI0409046A
BRPI0409046A BRPI0409046-2A BRPI0409046A BRPI0409046A BR PI0409046 A BRPI0409046 A BR PI0409046A BR PI0409046 A BRPI0409046 A BR PI0409046A BR PI0409046 A BRPI0409046 A BR PI0409046A
Authority
BR
Brazil
Prior art keywords
pks
systems
pufa
fatty acid
polyunsaturated fatty
Prior art date
Application number
BRPI0409046-2A
Other languages
English (en)
Portuguese (pt)
Inventor
James G Metz
Craig A Weaver
William R Barclay
James H Flatt
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of BRPI0409046A publication Critical patent/BRPI0409046A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
BRPI0409046-2A 2003-03-26 2004-03-26 sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos BRPI0409046A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45797903P 2003-03-26 2003-03-26
PCT/US2004/009323 WO2004087879A2 (en) 2003-03-26 2004-03-26 Pufa polyketide synthase systems and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0409046A true BRPI0409046A (pt) 2006-04-18

Family

ID=33131738

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409046-2A BRPI0409046A (pt) 2003-03-26 2004-03-26 sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos

Country Status (11)

Country Link
EP (1) EP1623008B1 (enExample)
JP (3) JP2007524377A (enExample)
KR (3) KR101234198B1 (enExample)
CN (1) CN101389213B (enExample)
AU (2) AU2004225485B2 (enExample)
BR (1) BRPI0409046A (enExample)
CA (1) CA2520396C (enExample)
ES (1) ES2516641T3 (enExample)
IL (1) IL200625A0 (enExample)
MX (2) MXPA05010214A (enExample)
WO (1) WO2004087879A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US8003772B2 (en) 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
ES2653545T3 (es) 2000-01-28 2018-02-07 Dsm Ip Assets B.V. Producción mejorada de lípidos que contienen ácidos grasos polienoicos por cultivos de alta densidad de microorganismos del orden Thraustochytriales en fermentadores
AU2006265801B2 (en) 2005-07-01 2011-07-14 Martek Biosciences Corporation Polyunsaturated fatty acid-containing oil product and uses and production thereof
GB0603160D0 (en) 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
US7759548B2 (en) 2006-03-15 2010-07-20 Martek Biosciences Corporation Polyunsaturated fatty acid production in heterologous organisms using PUFA polyketide synthase systems
CA2662260C (en) * 2006-08-29 2015-10-27 Martek Biosciences Corporation Use of dpa(n-6) oils in infant formula
EP2405018A4 (en) * 2009-03-04 2013-02-20 Univ Miyazaki METHOD FOR DETERMINING THE FATTY ACID SYNTHESIS PATH OF A MICROORGANISM AND PCR PRIMER FOR THIS METHOD
CA2755667C (en) * 2009-03-16 2018-06-12 Martek Biosciences Corporation Protein production in microorganisms of the phylum labyrinthulomycota
ES2717102T3 (es) 2009-03-19 2019-06-19 Dsm Ip Assets Bv Moléculas de ácido nucleico de ácido graso poliinsaturado sintasas, y polipéptidos, composiciones y métodos de preparación y usos de los mismos
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR101570771B1 (ko) 2013-11-18 2015-11-23 대한민국 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체
JP6682109B2 (ja) * 2015-01-09 2020-04-15 国立大学法人 宮崎大学 ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法
PL3455351T3 (pl) * 2016-05-12 2022-11-21 Dsm Ip Assets B.V. Sposób zwiększania wytwarzania wielonienasyconych kwasów tłuszczowych omega-3 w mikroalgach
WO2020032258A1 (ja) * 2018-08-10 2020-02-13 協和発酵バイオ株式会社 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法
US11613728B2 (en) 2018-08-10 2023-03-28 Kyowa Hakko Bio Co., Ltd. Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
IN1998CH01219A (en) * 1997-06-04 2005-03-04 Calgene Llc Production of polyunsaturated fatty acid by expression of polyketide-like synthesis genes in plants
US6566583B1 (en) * 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
CA2421267C (en) * 2000-09-28 2009-01-06 Bioriginal Food & Science Corporation Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
US6912470B2 (en) * 2001-05-21 2005-06-28 Ecopia Biosciences, Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
TWI337619B (en) * 2001-04-16 2011-02-21 Martek Biosciences Corp Pufa polyketide synthase systems and uses thereof

Also Published As

Publication number Publication date
KR101234200B1 (ko) 2013-02-19
AU2004225485B2 (en) 2008-08-21
KR20120123726A (ko) 2012-11-09
CN101389213B (zh) 2014-05-28
AU2004225485A1 (en) 2004-10-14
AU2008249169A1 (en) 2008-12-11
JP5890791B2 (ja) 2016-03-22
JP2013143945A (ja) 2013-07-25
KR101234198B1 (ko) 2013-02-19
AU2008249169B2 (en) 2012-03-15
KR20120097502A (ko) 2012-09-04
CA2520396A1 (en) 2004-10-14
KR20060006014A (ko) 2006-01-18
JP2007524377A (ja) 2007-08-30
IL200625A0 (en) 2011-07-31
JP6134361B2 (ja) 2017-05-24
CA2520396C (en) 2016-08-09
WO2004087879A2 (en) 2004-10-14
ES2516641T3 (es) 2014-10-31
CN101389213A (zh) 2009-03-18
EP1623008A4 (en) 2009-05-27
MX341785B (es) 2016-09-01
EP1623008B1 (en) 2014-07-30
HK1088632A1 (en) 2006-11-10
MXPA05010214A (es) 2005-12-14
WO2004087879A3 (en) 2008-07-24
JP2016000048A (ja) 2016-01-07
KR101234199B1 (ko) 2013-02-20
EP1623008A2 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
BRPI0409046A (pt) sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos
WO2002083870A3 (en) Pufa polyketide synthase systems and uses thereof
MX2007004502A (es) Sistemas de policetido de sintasa de ??cido graso poliinsaturado pufa y usos de los mismos.
BRPI0410681A (pt) moléculas de ácido nucléico isoladas, polipeptìdio, gene quimérico, célula hospedeira transformada, métodos para a produção de ácido linoléico e de ácidos graxos w-3, método para modular a biosìntese de ácidos graxos w-3 ou w-6, óleo microbial, e métodos para a obtenção de uma molécula de ácido nucléico
JP2004504001A (ja) スプライソソーム媒介ｒｎａトランスースプライシングにおける使用のための方法及び組成物
AU5753598A (en) Novel genes coding for amino acid deacetylases with specificity for N-acetyl-L-phosphinothricin, their isolation and use
WO2006135866A3 (en) Pufa polyketide synthase systems and uses thereof
SE9803838D0 (sv) A chromatography method and a column material useful in said method
NO20101157L (no) FAD4, FAD5, FAD5-2 og FAD6, nye fettsyredesaturase familiemedlemmer og anvendelser derav
ID29136A (id) Suatu proses untuk pembuatan asam karboksilat kiral dari nitril dengan menggunakan suatu nitrilase atau mikroorganisme yang terdiri dari suatu gen untuk nitrilase
BR0116033A (pt) Amplificação isotérmica de ácidos nucléicos sobre um suporte sólido
ATE299945T1 (de) Verfahren zur herstellung von l-aminosäuren
DK1411116T3 (da) Peptidsyntasegen, peptidsyntase samt fremgangsmåde til fremstilling af dipeptid
BR0006909A (pt) Sequências de nucleotìdeos que codificam o gene de opca
BR0014663A (pt) Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias
BR0011033A (pt) Métodos de purificação de dna e dna purificado
DE60042178D1 (de) Gene, welche für Flavon-Synthasen kodieren
WO2005058945A3 (de) Genvarianten die für proteine aus dem stoffwechselweg von feinchemikalien kodieren
BR0102669A (pt) Bactéria corineforme, método para produzir ácido l-glutâmico, e, dna
BR9905785A (pt) Processo de fermantação para a preparação de ácido d-panto-tênico utilizando cepas da famìlia enterobacteriaceae
ID29693A (id) Rangkaian-rangkaian nukleotida yang mengkode gen dapc dan proses untuk memproduksi l-lisin
ATE525465T1 (de) Neue gene für transferasen aromatischer acylgruppen
BR0212530A (pt) Proteìnas reforçadas e métodos para seu uso
BR0002493A (pt) Processo para a preparação de l-aminoácidos por fermentação e sequências de nucleotìdeos que codificam o gene accda
BRPI0507978A (pt) bactéria produtora de l-aminoácido pertencente à famìlia enterobacteriaceae, e, método para produzir um l-aminoácido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DSM IP ASSETS B.V. (NL)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL